Changes in protein arginine methylation by GSK3368712

ABSTRACT: Type I Protein Arginine Methyltransferases (PRMTs) catalyze asymmetric dimethylation of arginine residues on numerous proteins. Type I PRMTs and their substrates have been implicated in human cancers, suggesting that inhibiting Type I PRMT activity offers a tractable approach for therapeutic intervention. This dataset contains results from immunoproteomic studies enriching for monomethylated, asymmetrically, and symmetrically dimethylated arginines in cancer cell lines treated with the Type I PRMT inhibitor, GSK3368712.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Adenocarcinoma Cell Line, Leukocyte, Lymph Node

DISEASE(S): Pancreatic Cancer,Lymphoma

SUBMITTER: Vicky Yang  

LAB HEAD: Helai Mohammad

PROVIDER: PXD012747 | Pride | 2019-09-10

REPOSITORIES: Pride